The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
Open accessAbstract
BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) occurs in approximately 3% of persons 50 years of age or older. METHODS: We studied 1384 patients who were residing in southeastern Minnesota and in whom MGUS was diagnosed at the Mayo Clinic in the period from 1960 through 1994; the median follow-up was 34.1 years (range, 0.0 to 43.6). The primary end point was progression to multiple myeloma or another plasma-cell or lymphoid disorder. RESULTS: During 14,130 person-years of follow-up, MGUS progressed in 147 patients (11%), a rate that was 6.5 times (95% confidence interval [CI], 5.5 to 7.7) as high as the rate in the control population. The risk of progression without accounting for death due to competing causes was 10% at 10 years, 18% at 20 years, 28% at 30 years, 36% at 35 years, and 36% at 40 years. Among patients with IgM MGUS, the presence of two adverse risk factors - namely, an abnormal serum free light-chain ratio (ratio of kappa to lambda free light chains) and a high serum monoclonal protein (M protein) level (≥1.5 g per deciliter) - was associated with a risk of progression at 20 years of 55%, as compared with 41% among patients who had one adverse risk factor and 19% among patients who had neither risk factor. Among patients with non-IgM MGUS, the risk of progression at 20 years was 30% among those who had the two risk factors, 20% among those who had one risk factor, and 7% among those who had neither risk factor. Patients with MGUS had shorter survival than was expected in the control population of Minnesota residents of matched age and sex (median, 8.1 vs. 12.4 years; P<0.001). CONCLUSIONS: Significant differences were noted in the risk of progression between patients with IgM MGUS and those with non-IgM MGUS. Overall survival was shorter among patients with MGUS than was expected in a matched control population. (Funded by the National Cancer Institute.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This tumor does not develop rapidly; instead, it may take decades for symptoms and organ damage to manifest.4-8”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MM is well-described to be universally preceded by precursor states, often decades before it is even diagnosed.”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several epidemiological studies have shown that patients with MGUS and SMM might experience progression to MM over an extremely variable timeframe. Some patients progressed to MM within 2 years of diagnosis, while others may progress after 10 to 20 years or might never progress at all.4-6,75”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“MGUS progresses to multiple myeloma or related malignancy a rate of 1% per year.16,17”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationAsymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Tutorial in biostatistics: competing risks and multi‐state models
Putter, H., Fiocco, M. F., & Geskus, R. B. (2006) · Statistics in Medicine · doi:10.1002/sim.2712 · Cited by 2,458
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationHistory of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Prevalence of monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423
Self-citation
Flagged first, then by citations
1 of the 30 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Kyle R Katzmann JA. Immunochemical characterization of immunoglobulins. In: Rose NR Conway de Macario E Folds JD Lane HC Nakamura RM eds. Manual of clinical laboratory immunology. 5th ed. Washington DC: ASM Press 1997:156-76.
Cited by
Sorted by citations
Items 201–300 of 646
Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma
Schmidt, T. M., & Callander, N. S. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7660 · Cited by 14
Trojani, A., Camillo, B. D., Bossi, L. E., Leuzzi, L., Greco, A., Tedeschi, A., Frustaci, A. M., Deodato, M., Zamprogna, G., Beghini, A., et al. (2021) · Cancers · doi:10.3390/cancers13081837 · Cited by 13
Jin, Y., Savage, N. M., Bollag, R. J., Xu, H., & Singh, G. (2021) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfab090 · Cited by 12
A polygenic risk score for multiple myeloma risk prediction
Canzian, F., Piredda, C., Macauda, A., Zawirska, D., Andersen, N. F., Nagler, A., Zaucha, J. M., Mazur, G. J., Dumontet, C., Wątek, M., et al. (2021) · European Journal of Human Genetics · doi:10.1038/s41431-021-00986-8 · Cited by 12
Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises
Alkharabsheh, O. A., Trisel, Z. M., Badami, S., Aljama, M. A., & Sidiqi, M. H. (2021) · Cancers · doi:10.3390/cancers14010113 · Cited by 13
Chang, V. C., Khan, A. A., Huang, W., Katki, H. A., Purdue, M. P., Landgren, O., & Hofmann, J. N. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00642-4 · Cited by 12
Mortality in the US Populations With Monoclonal Gammopathy of Undetermined Significance
Ji, M., Huber, J. H., Schoen, M. W., Sanfilippo, K. M., Colditz, G. A., Wang, S., & Chang, S. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2278 · Cited by 12
Latov, N., Brannagan, T. H., Sander, H. W., & Gondim, F. D. A. A. (2024) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1777728 · Cited by 12
Bustoros, M. W., Kastritis, E., Sklavenitis‐Pistofidis, R., Liu, C., Hornburg, K., Kanellias, N., Kim, P. G., Liu, D., Gavriatopoulou, M., Marinac, C. R., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25441 · Cited by 12
Cárdenas, M. C., García‐Sánz, R., Puig, N., Pérez-Surribas, D., Flores-Montero, J. A., Ortiz-Espejo, M., de la Rubia, J., & Cruz-Iglesias, E. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0326 · Cited by 11
Grandhi, N., Liu, L., Wang, M., Thomas, T. S., Schoen, M. W., Sanfilippo, K. M., Gao, F., Colditz, G. A., Carson, K. R., Janakiram, M., et al. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae095 · Cited by 12
Modeling the Bone Marrow Niche in Multiple Myeloma: From 2D Cultures to 3D Systems
Bottaro, A., Nasso, M. E., Stagno, F., Fazio, M., & Allegra, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136229 · Cited by 13
Search for AL amyloidosis risk factors using Mendelian randomization
Saunders, C. N., Chattopadhyay, S., Huhn, S., Weinhold, N., Hoffmann, P., Nöthen, M. M., Jöckel, K., Schmidt, B., Landi, S., Goldschmidt, H., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004423 · Cited by 11
Späth, F., Wibom, C., Krop, E. J. M., Izarra, A., Johansson, A.-S., Bergdahl, I. A., Hultdin, J., Vermeulen, R. C. H., & Melin, B. S. (2019) · Haematologica · doi:10.3324/haematol.2019.216895 · Cited by 11
Clinical Controversies in the Management of Smoldering Multiple Myeloma
Lomas, O., & Ghobrial, I. M. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_278911 · Cited by 11
Eton, E. A., Abrams, G., Khan, N., & Fahim, A. T. (2020) · BMC Ophthalmology · doi:10.1186/s12886-020-01423-y · Cited by 11
Manzoni, M., Marchica, V., Storti, P., Ziccheddu, B., Sammarelli, G., Todaro, G., Pelizzoni, F., Salerio, S., Notarfranchi, L., Pompa, A., et al. (2020) · Cancers · doi:10.3390/cancers12051332 · Cited by 11
Baldursdóttir, T. R., Löve, Þ. J., Gíslason, G. K., Björkholm, M., Mellqvist, U., Lund, S. H., Blimark, C. H., Turesson, I., Hultcrantz, M. L., Landgren, O., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13563 · Cited by 11
Tamayo, R. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00121-9 · Cited by 13
Lim, S. M., Wijeratne, N. G., Choy, K. W., Nguyen, T. T. H., Setiawan, L., & Loh, T. P. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2257306 · Cited by 10
Extracellular vesicles as next-generation therapeutics and biomarkers in amyloidosis: a new frontier
Phan, T. H., & Reed, J. H. (2024) · Frontiers in Biomaterials Science · doi:10.3389/fbiom.2023.1343658 · Cited by 10
Óskarsson, J. Þ., Rögnvaldsson, S., Þorsteinsdóttir, S., Long, T. E., Ólafsson, A., Eyþórsson, E. S., Jónsson, Á., Viðarsson, B., Onundarson, P. T., Agnarsson, B. A., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01201-9 · Cited by 10
Li, J., Wang, Y., & Liu, P. (2019) · Journal of Cancer · doi:10.7150/jca.32103 · Cited by 10
Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma
Gozzetti, A. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028668 · Cited by 10
Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma
El-Masri, B. M., Leka, B., Mustapha, F., Gundesen, M. T., Hinge, M., Lund, T., Andersen, T. L., Diaz‐delCastillo, M., & Jafari, A. (2024) · Oncotarget · doi:10.18632/oncotarget.28548 · Cited by 10
Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma
Kumar, S. K., Glazebrook, K. N., & Broski, S. M. (2019) · PET Clinics · doi:10.1016/j.cpet.2019.03.006 · Cited by 10
Self-citationCXCR4-targeted PET imaging using 64Cu-AMD3100 for detection of Waldenström Macroglobulinemia
Muz, B., Bandara, N., Mpoy, C., Sun, J., Alhallak, K., Azab, F., Rogers, B. E., & Azab, A. K. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1665405 · Cited by 10
Kumar, L., Nair, S., Vadlamani, S. P., & Chaudhary, P. (2020) · Journal of Current Oncology · doi:10.4103/jco.jco_43_20 · Cited by 10
Lamb, M. J. E., Smith, A. G., Painter, D., Kane, E. V., Bagguley, T., Newton, R., Howell, D. A., Cook, G., Tute, R. M. D., Rawstron, A. C., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-041296 · Cited by 10
M-protein–related disorders: MGCS
Bladé, J., & Cibeira, M. T. (2018) · Blood · doi:10.1182/blood-2018-07-865642 · Cited by 10
Expert-level detection of M-proteins in serum protein electrophoresis using machine learning
Elfert, E., Kaminski, W. E., Matek, C., Hoermann, G., Axelsen, E. W., Marr, C., & Piehler, A. P. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-0222 · Cited by 10
Risk of Hematologic Malignancies in Patients With Acute Myocardial Infarction
Yoon, S. Y., Kim, M., Kim, H., Bang, D. W., Park, B., Jeong, S. Y., Lee, M.-Y., Kim, K. H., Lee, N.-S., Won, J.-H., et al. (2025) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.04.003 · Cited by 9
Management recommendations for kidney transplantation in patients with plasma cell dyscrasia
Murakami, N., Blosser, C. D., Webber, A. B., Gupta, G., Singh, N., Boppana, S., Master, S. R., Parasuraman, R. K., Campagnaro, E. L., Java, A., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.07.011 · Cited by 10
Mangaonkar, A. A., Bolton, K. L., & Patnaik, M. M. (2026) · American Journal of Hematology · doi:10.1002/ajh.70205 · Cited by 11
Li, J., Tan, H., Xu, T., Shi, H., & Liu, P. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04629-2 · Cited by 10
Oral Lichen Planus and Mutated TP53—A Road to Cancer?
Holbrook, W. P., & Ogmundsdottir, H. M. (2022) · Dentistry Journal · doi:10.3390/dj10090176 · Cited by 9
Naum, R., & Gwathmey, K. G. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-98818-6.00004-2 · Cited by 9
Screening in Multiple Myeloma and Its Precursors: Are We There Yet?
Rögnvaldsson, S., Þorsteinsdóttir, S., & Kristinsson, S. Y. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvad148 · Cited by 10
Association Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance
Sverrisdottir, I. S., Þorsteinsdóttir, S., Rögnvaldsson, S., Aspelund, T., Viðarsson, B., Onundarson, P. T., Agnarsson, B. A., Sigurðardóttir, M. S., Þorsteinsdóttir, I., Sveinsdottir, S. V., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-2867 · Cited by 9
MGCS: where do we stand today?
Iberri, D. J., & Liedtke, M. (2024) · Hematology · doi:10.1182/hematology.2024000572 · Cited by 9
The Evolution of Monoclonal Gammopathy of Undetermined Significance in Kidney Transplant Recipients
Gagnon, M.-F., Cardinal, H., Émond, J.-P., Latour, M., & Lemieux, B. (2019) · Transplantation Direct · doi:10.1097/txd.0000000000000937 · Cited by 9
Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma
Jamet, B., Bailly, C., Carlier, T., Touzeau, C., Michaud, A.-V., Bourgeois, M., Moreau, P., Bodet‐Milin, C., & Kraeber‐Bodéré, F. (2020) · Cancers · doi:10.3390/cancers12020486 · Cited by 9
Thomas, S. K. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.11.014 · Cited by 9
The molecular biology of multiple myeloma
Chng, W. J., & Bergsagel, P. L. (2019) · Wiley eBooks · doi:10.1002/9781119252863.ch10 · Cited by 9
Three‐dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma
Kumar, S. K., Rajkumar, S. V., Jevremović, D., Kyle, R. A., Shifrin, Y., Nguyen, M. A., Husain, Z., Alikhah, A., Jafari, A., Mai, S., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27364 · Cited by 8
Self-citationVu, T., Wang, Y., Fowler, A., Simieou, A., & McCarty, N. (2024) · Cells · doi:10.3390/cells13171431 · Cited by 8
Moreno, D. F., Jiménez, C., Escalante, F., Askari, E., Castellanos‐Alonso, M., Arnao, M., Heredia, Á., Canales, M. Á., Alcalá, M., Bermúdez, A., et al. (2024) · HemaSphere · doi:10.1002/hem3.70029 · Cited by 8
Chojnacka, M., Diamond, B. T., Landgren, O., & Maura, F. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.006 · Cited by 8
Histological Findings in Kidney Biopsies of Patients with Monoclonal Gammopathy—Always a Surprise
Klank, D., Hoffmann, M. F., Porubský, Š., & Bergner, R. (2022) · Diagnostics · doi:10.3390/diagnostics12081912 · Cited by 8
Rodríguez-García, A., Mennesson, N., Hernández, G., Morales, M. L., Garderet, L., Bouchereau, L., Allain‐Maillet, S., Piver, É., Alvarez, I. M., Ruiz, D. R., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283096 · Cited by 8
Cardiovascular toxicity from therapies for light chain amyloidosis
Morfino, P., Aimo, A., Castiglione, V., Chianca, M., Vergaro, G., Cipolla, C. M., Fedele, A., Emdin, M., Fabiani, I., & Cardinale, D. M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1212983 · Cited by 8
Artificial intelligence in serum protein electrophoresis: history, state of the art, and perspective
He, H., Wang, L., Wang, X., & Zhang, M. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2274325 · Cited by 8
Pérez‐Escurza, O., Flores-Montero, J. A., Óskarsson, J. Þ., Sanoja-Flores, L., Pozo, J., Lécrevisse, Q., Martín, S., Reed, E. R., Hákonardóttir, G. K., Harding, S. J., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00944-1 · Cited by 12
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS
Bravo‐Pérez, C., & Gurnari, C. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.01.004 · Cited by 8
Lu, C., He, D., Wang, R., Mou, H., Bi, G., Liu, C., Zhou, G., & Bao, P. (2024) · Clinical Rheumatology · doi:10.1007/s10067-024-07062-8 · Cited by 8
DNA vaccines against GPRC5D synergize with PD-1 blockade to treat multiple myeloma
Neeli, P. K., Maza, P. A. M., Chai, D., Zhao, D., Hoi, X. P., Chan, K. S., Young, K. H., & Li, Y. (2024) · npj Vaccines · doi:10.1038/s41541-024-00979-w · Cited by 9
Li, X., Hao, Y., Xue, R., Qi, X., & Ma, Z. (2019) · Medicine · doi:10.1097/md.0000000000014557 · Cited by 8
Jalali, S., Shi, J., Ahsan, N., Wellik, L. E., Serres, M. R., BUKO, A. M., Paludo, J., Kim, H.-J., Tang, X.-Y., Yang, Z., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101927 · Cited by 10
Self-citationVasco-Mogorrón, M. A., Campillo, J. A., Periago, A., Cabañas, V., Berenguer, M., García-Garay, M. C., Gimeno, L., Soto‐Ramírez, M. F., Martínez-Hernández, M. D., Muro, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083895 · Cited by 8
Drandi, D., Decruyenaere, P., Ferrante, M., Offner, F. C., Vandesompele, J., & Ferrero, S. (2022) · Diagnostics · doi:10.3390/diagnostics12040969 · Cited by 8
Cingam, S. R., & Sidana, S. (2022) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s259860 · Cited by 8
Systemic Amyloidosis and Kidney Transplantation: An Update
Anand, S. K., Sanchorawala, V., & Verma, A. (2024) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2024.151496 · Cited by 8
Association of Monoclonal Gammopathy with Progression to ESKD among US Veterans
Burwick, N. R., Adams, S. V., Todd–Stenberg, J. A., Burrows, N. R., Pavkov, M. E., & O’Hare, A. M. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06210518 · Cited by 8
Peña, C., Schutz, N. P., Riva, E., Valjalo, R., Majlis, A., López‐Vidal, H., Lois, V., Zamora, D., Ochoa, P. A., Shanley, C. M., et al. (2019) · Nephrology · doi:10.1111/nep.13685 · Cited by 8
Więsik–Szewczyk, E., Felis‐Giemza, A., Dziuk, M., & Jahnz‐Różyk, K. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s265482 · Cited by 8
Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy
Moreno, D. F., Pereira, A., Tovar, N., Cibeira, M. T., Magnano, L., Rozman, M., López‐Guerra, M., Colomer, D., Martín-Antonio, B., Jiménez‐Segura, R., et al. (2021) · Cancers · doi:10.3390/cancers13092055 · Cited by 8
Evolution of Multiple Myeloma from a Genomic Perspective
Maura, F., Samur, M., & Munshi, N. (2026) · Blood · doi:10.1182/blood.2024026313 · Cited by 8
Multimorbidity in patients with monoclonal gammopathy of undetermined significance
Epstein, M. M., Zhou, Y., Castañeda‐Avila, M. A., & Cohen, H. J. (2023) · International Journal of Cancer · doi:10.1002/ijc.34476 · Cited by 7
Schmidt, T. M., Gahvari, Z. J., & Callander, N. S. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.03.008 · Cited by 8
Hannich, M. J., Konen, F. F., Gag, K., Alkhayer, A., Türker, S. N., Budde, K., Nauck, M., Wurster, U., Dressel, A., Skripuletz, T., et al. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-1468 · Cited by 7
FaMMily Affairs: Dissecting inherited contributions to multiple myeloma risk
Bodnar, S., Brander, T., Gold, J., Iverson, A. A., Laganà, A., Onel, K., Jagannath, S., Parekh, S. S., & Thibaud, S. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.11.006 · Cited by 7
Li, Y., Hsu, S. H., Wang, R., Theprungsirikul, P. P., Neparidze, N., Chang, S., & Wang, S. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.12.006 · Cited by 7
Fenton, A., Chinnadurai, R., Gullapudi, L., Kampanis, P., Dasgupta, I., Ritchie, J. P., Harding, S. J., Ferro, C. J., Kalra, P. A., Taal, M. W., et al. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003050 · Cited by 7
From pathogenesis to personalized treatments of neuropathies in hematological malignancies
Briani, C., Visentin, A., Cerri, F., & Quattrini, A. (2020) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12405 · Cited by 7
Liang, D., Liu, J., Liang, S., Xu, F., Cheng, Z., Huang, X., Zeng, C., & Liu, Z. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00817-x · Cited by 7
Omar, N., Madwani, K., Moideen, P., Manthei, D. M., Keren, D. F., & Singh, G. (2021) · Laboratory Medicine · doi:10.1093/labmed/lmab055 · Cited by 7
Kang, K., Song, J. E., Lee, B., Jeon, M. J., Yu, E. S., Kim, D. S., Lee, S. R., Sung, H. J., Choi, C. W., Park, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97664-y · Cited by 7
Visram, A., Vachon, C. M., Baughn, L. B., Larson, D. R., Smadbeck, J. B., Dispenzieri, A. A., Kapoor, P., Lacy, M. Q., Gertz, M. A., Buadi, F. K., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01454-4 · Cited by 7
Self-citationBradey, A. L., Fitter, S., Duggan, J., Wilczek, V. J., Williams, C. M. D., Cheney, E. A., Noll, J. E., Tangseefa, P., Panagopoulos, V., & Zannettino, A. C. W. (2022) · Scientific Reports · doi:10.1038/s41598-022-17403-9 · Cited by 7
Identifying monoclonal gammopathy of undetermined significance in electronic health data
Epstein, M. M., Saphirak, C., Zhou, Y., Leblanc, C., Rosmarin, A. G., Ash, A. S., Singh, S., Fisher, K. A., Birmann, B. M., & Gurwitz, J. H. (2019) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4912 · Cited by 7
Wang, W., Shim, Y. K., Michalek, J. E., Barber, E., Saleh, L. M., Choi, B. Y., Wang, C., Ketchum, N. S., Costello, R., Marti, G. E., et al. (2020) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2020.1749919 · Cited by 7
Cardiovascular Associations With Monoclonal Gammopathy of Undetermined Significance
Kapoor, P., & Rajkumar, S. V. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.07.002 · Cited by 7
Self-citationMulti-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes
Kolijn, P. M., Smith-Byrne, K., Burk, V. A., Viallon, V., Lee, M. A., Papier, K., Wang, Z., Langerak, A. W., Späth, F., Diepstra, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64534-4 · Cited by 6
The Gut Microbiome Role in Multiple Myeloma: Emerging Insights and Therapeutic Opportunities
George, M. Y., Gamal, N. K., Mansour, D. E., Famurewa, A. C., Bose, D., Messiha, P. A., & Cerchione, C. (2025) · Hematology Reports · doi:10.3390/hematolrep17060056 · Cited by 6
Management of monoclonal gammopathy of renal significance: treatment standard
Jaturapisanukul, S., Nasr, S. H., & Leung, N. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf254 · Cited by 6
Berg, S. R., Dikic, A., Sharma, A., Hagen, L., Vågbø, C. B., Zatula, A., Misund, K., Waage, A., & Slupphaug, G. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05345-x · Cited by 8
Lahuna, C., Defendi, F., Bouillet, L., Boccon‐Gibod, I., MEKINIAN, A., Coppo, P., Adamski, H., Amarger, S., Armengol, G., Aubineau, M., et al. (2024) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2024.09.016 · Cited by 6
Karathanasis, N., & Spyrou, G. M. (2025) · Cancers · doi:10.3390/cancers17020332 · Cited by 8
Paraproteinemias and Peripheral Nerve Disease
Leavell, Y. L., & Shin, S. C. (2021) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2021.01.004 · Cited by 6
Clinicopathological characteristics of patients with paraproteinemia and renal damage
Tang, X., Wan, F., Yü, J., Li, X., Yang, R., & Zhu, B. (2021) · European journal of medical research · doi:10.1186/s40001-021-00538-2 · Cited by 6
Clinical significance of human endogenous retrovirus K (HERV-K) in multiple myeloma progression
Masuda, Y., Ishihara, R., Murakami, Y., Watanabe, S., Asao, Y., Gotoh, N., Kasamatsu, T., Takei, H., Kobayashi, N., Saitoh, T., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03513-7 · Cited by 6
Lewis, E., Lee, H., Fine, N. M., Miller, R. J. H., Hahn, C., Tay, J., Chhibber, S., Mahé, E., & Jimenez-Zepeda, V. H. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.12.012 · Cited by 6
Ishihara, R., Oda, T., Murakami, Y., Matsumura, I., Watanabe, S., Asao, Y., Masuda, Y., Gotoh, N., Kasamatsu, T., Takei, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032216 · Cited by 6
Tentolouris, A., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Andreadou, I., & Terpos, E. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10120484 · Cited by 6
Wang, W., Li, J., Yang, Y., Chen, F., Xu, T., Wang, P., Wang, Y., Maihemaiti, A., Ren, L., Lan, T., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6859 · Cited by 6
He, H., Wang, Z., Xu, J., Liu, Y., Shao, Y., Hou, Y., Gu, J., Hu, R., & Xing, G. (2024) · Scientific Reports · doi:10.1038/s41598-024-58467-z · Cited by 6
Shimamura, Y., Maeda, T., Ogawa, Y., Nagai, Y., Shinohara, T., & Takizawa, H. (2019) · CEN Case Reports · doi:10.1007/s13730-019-00438-9 · Cited by 6
Škerget, M., Dovšak, T., Kos, G., & Zver, S. (2020) · Hematology Reports · doi:10.4081/hr.2020.8396 · Cited by 6
Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance
Aslam, N., Trautman, C. L., & Sher, T. (2021) · Transplantation Direct · doi:10.1097/txd.0000000000001176 · Cited by 6
The Ins and Outs of Endosteal Niche Disruption in the Bone Marrow: Relevance for Myeloma Oncogenesis
Capp, J., & Bataille, R. (2023) · Biology · doi:10.3390/biology12070990 · Cited by 6
Metadata
- Authors
- Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A., Kumar, S., Cerhan, J. R., & Rajkumar, S. V.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-01-18
- Volume
- 378
- Issue
- 3
- Pages
- 241-249
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5852672
- OpenAlex
- W2785817645
- Cited by
- 647
- References
- 30
- Citations by year
- 2026: 62 · 2025: 90 · 2024: 101 · 2023: 81 · 2022: 75 · 2021: 76 · 2020: 80 · 2019: 47 · 2018: 33
- FWCI
- 42.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA107476, CA168762, CA186781)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- monoclonal gammopathy of undetermined significance, progression to multiple myeloma, plasma cell dyscrasia, free light chain ratio, risk factors, survival, long-term follow-up
- MeSH terms
- Adult, Aged, Bone Marrow Examination, Female, Follow-Up Studies, Glycoproteins, Humans, Immunoglobulin M, Immunoglobulin Light Chains, Male, Middle Aged, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Prognosis, Risk Factors, Proportional Hazards Models, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
